Bevacizumab (Avastatin)
Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date
Onco Targets and Therapy 2017 April [Link] Levin PA, Dowell JE Abstract Malignant pleural mesothelioma (MPM) is a rare, but aggressive cancer. Surgery and radiation offer limited benefit, and systemic chemotherapy remains the primary treatment modality for the majority of patients. Vascular endothelial growth factor (VEGF) and its receptor have been recognized as important players…
Read MoreTargeting the vasculature: anti-angiogenic agents for malignant mesothelioma
Expert Review of Anticancer Therapy 2016 October 4 [Epub ahead of print] [Link] Chia PL, Russell P, Scott AM, John T Abstract INTRODUCTION: Malignant mesothelioma (MM) is an aggressive malignancy of the pleura and other serosal membranes originating from mesothelial cells that, despite decades of research, continues to have limited therapeutic options and is associated…
Read MoreNCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016
Journal of the National Comprehensive Cancer Network 2016 July 14 [Link] Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D’Amico TA, Dilling T, Dobelbower M, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins…
Read MoreMicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients
Genomics Data 2016 June 20 [Link] Lin RC, Kirschner MB, Cheng YY, van Zandwijk N, Reid G Abstract Malignant pleural mesothelioma (MPM) is a tumor originating in the mesothelium, the membrane lining the thoracic cavities, and is induced by exposure to asbestos. Australia suffers one of the world’s highest rates of MPM and the incidence…
Read MoreProgranulin and granulin-like protein as novel VEGF-independent angiogenic factors derived from human mesothelioma cells
Oncogene 2016 June 27 [Epub ahead of print] [Link] Eguchi R, Nakano T, Wakabayashi I. Abstract Malignant mesothelioma is an aggressive tumor arising from the mesothelial cells of serous membranes and is associated with tumor angiogenesis, which is a prerequisite for tumor progression. Vascular endothelial growth factors (VEGFs) including VEGF-A have a crucial role in…
Read MoreBevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
Lancet 2015 December 21 [Epub ahead of print] [Link] Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup…
Read MoreAdvanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed
Journal of Controlled Release 2015 October 18 [Epub ahead of print] [Link] Ando H, Kobayashi S, Abu Lila AS, Eldin NE, Kato C, Shimizu T, Ukawa M, Kawazoe K, Ishida T. Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer that proliferates in the pleural cavity. Pemetrexed (PMX) in combination with cisplatin is currently the…
Read MorePemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)
Therapeutics and Clinical Risk Management. 2008 Jun;4(3):579-85. [Link] Felip E, Rosell R. Vall d’Hebron University Hospital Barcelona, Spain. Abstract NSCLC accounts for 80% of all cases of lung cancer, which is the leading cause of cancer mortality. The majority of NSCLC patients present with advanced, unresectable disease, which remains incurable. In advanced disease, chemotherapy with…
Read MoreErlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
Cancer. 2008 Jun 9. [Epub ahead of print] [Link] Jackman DM, Kindler HL, Yeap BY, Fidias P, Salgia R, Lucca J, Morse LK, Ostler PA, Johnson BE, Jänne PA. Danaâ€Farber Cancer Institute, Boston, Massachusetts. Abstract Background: We conducted a phase 2, multicenter, open-label study of erlotinib plus bevacizumab in patients with malignant pleural mesothelioma who…
Read MoreRestrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599
Clinical Lung Cancer. 2008 Mar;9(2):102-5. [Link] Somer RA, Sherman E, Langer CJ. Department of Medical Oncology, Cooper Medical Center, Cherry Hill, NJ, USA. Abstract Background: In a previous randomized phase II trial evaluating carboplatin and paclitaxel with or without bevacizumab in patients naive to chemotherapy with advanced non-small-cell lung cancer (NSCLC), median survival ranged from…
Read More